Aspire Biopharma Holdings (ASBP) Company Report

Aspire Biopharma Holdings, Inc. (ASBP) filed a Certificate of Designation on February 2, 2026, designating 25,000 shares of its authorized and unissued preferred stock as Series A Convertible Preferred Stock, each with a Stated Value of $1,000.
The Series A shares are convertible into Common Stock at the holder's option, with a Conversion Price equal to 80% of the lowest closing price of the Common Stock over the five trading days prior to conversion, but not less than the Floor Price.
Conversion is subject to limitations, including a beneficial ownership cap of 4.99% (which can be increased to 9.99%) and a 19.99% ownership limitation unless shareholder approval is obtained as required by Nasdaq Listing Rule 5636(d).
The Series A ranks senior to Common Stock and Junior Securities regarding dividends and liquidation distributions, and includes price protection and participation rights in future financings.

9 hours ago

Aspire Biopharma Holdings, Inc. Secures $2 Million in Debt Financing

ASBP

Debt Issuance

Aspire Biopharma Holdings, Inc. (ASBP) entered into a Securities Purchase Agreement on January 26, 2026, to sell 8% OID Debentures.
The aggregate principal amount of the Debentures is $2,173,913.04, sold for a subscription price of $2,000,000.
The Debentures mature on April 23, 2026, or earlier if the company receives at least $8,000,000 in debt or equity financing.
In connection with this financing, purchasers received 790,000 shares of ASBP's common stock as incentive shares.
The company intends to use the proceeds to pay off debt and for working capital purposes.

7 days ago

Aspire Biopharma Holdings, Inc. Announces Debt-to-Equity Exchange Agreement

ASBP

Aspire Biopharma Holdings, Inc. (ASBP) entered into Exchange Agreements on January 1, 2026, to convert approximately $1.75 million in debt into common stock.
This debt originated from subscription agreements made by the company's predecessor, PowerUp Acquisition Corp., in March and May 2024, with the debt holders being Sponsors of PowerUp's initial public offering.
Debt holders can submit up to four exchange notices by January 31, 2026, with the exchange price set at the closing price of the common stock on the day prior to the exchange notice, less $0.01.
The company retains an option to repay the debt in cash if it secures a financing exceeding $3,000,000, allowing holders to elect to receive cash proceeds up to 25% of their outstanding balance or up to 33.33% of the financing proceeds.

Jan 6, 2026, 1:35 PM

ASBP Enters New $100 Million Equity Line of Credit Agreement

ASBP

Aspire Biopharma Holdings, Inc. (ASBP) entered into a new Equity Line of Credit (ELOC) Agreement with Arena Business Solutions Global SPC II, Ltd. on November 11, 2025, granting ASBP the right to sell up to $100,000,000 in common stock to Arena.
The purchase price for shares under the ELOC Agreement will be 96% of the Volume Weighted Average Price (VWAP) of ASBP's common stock during the trading day.
This new ELOC Agreement replaces a previous one with Arena, which was mutually terminated on the same date, November 11, 2025.
In consideration for the agreement, ASBP will cover Arena's due diligence and legal fees totaling $40,000, with $20,000 paid upon execution and the remainder by issuing 162,338 shares of common stock.

Nov 14, 2025, 1:00 PM

Get instant answers from SEC filings, earnings calls & more